Valuation: Bicycle Therapeutics plc

Market Cap 308M 270M 250M 230M 435M 29.47B 444M 2.98B 1.17B 14.47B 1.16B 1.13B 49.97B P/E 2026 *
-1.89x
P/E 2027 * -2.1x
Enterprise Value -204M -179M -166M -153M -289M -19.54B -294M -1.98B -775M -9.59B -767M -750M -33.13B EV / Sales 2026 *
-11.2x
EV / Sales 2027 * -6.82x
Free-Float
6.21%
Yield 2026 *
-
Yield 2027 * -
1 day-1.36%
Current month+2.59%
1 month+4.82%
3 months-12.65%
6 months-32.97%
Current year-38.56%
1 week 4.08
Extreme 4.075
4.52
1 month 3.92
Extreme 3.92
4.52
Current year 3.92
Extreme 3.92
7.34
1 year 3.92
Extreme 3.92
9.18
3 years 3.92
Extreme 3.92
28.67
5 years 3.92
Extreme 3.92
62.08
10 years 3.92
Extreme 3.92
62.08
Manager TitleAgeSince
Chief Executive Officer 57 01/09/2015
Director of Finance/CFO 46 29/01/2026
Chief Tech/Sci/R&D Officer - 01/06/2025
Director TitleAgeSince
Director/Board Member 57 01/09/2015
Director/Board Member 63 17/03/2021
Director/Board Member 69 20/02/2024
Date Insider Type Main position Quantity % Market Cap.
06/07Sell

Chief Operating Officer

-376 0.0010%
06/07Sell

Chief Financial Officer

-104 0.0003%
06/07Sell

CHIEF PROD & SUPPLY CHAIN OFF

-255 0.0007%
Change 5-day change 1-year change 3-year change Capi.($)
-1.36%0.00%-46.16%-83.43% 308M
-2.48%-3.13%+55.85%+89.65% 54.88B
-0.55%-6.57%+55.85%+128.31% 54.63B
-5.60%-2.15%+7.12%+420.46% 25.06B
-1.55%-4.11%-18.86%-17.75% 23.14B
-1.69%-0.64%+40.04%-0.48% 19.87B
+1.87%+4.16%+38.74%-26.42% 17.55B
-2.72%-0.60%+187.08%+351.91% 16.5B
-2.42%+1.00%+48.24%+635.77% 15.75B
-0.81%+0.92%+22.95%+189.61% 14.2B
Average -1.64%-0.60%+39.08%+168.76% 24.19B
Weighted average by Cap. -1.73%-1.56%+47.51%+165.66%

Financials

2026 *2027 *
Net sales 18.24M 15.99M 14.81M 13.63M 25.78M 1.75B 26.28M 177M 69.25M 857M 68.48M 66.98M 2.96B 14.11M 12.38M 11.46M 10.55M 19.95M 1.35B 20.34M 137M 53.59M 663M 52.99M 51.84M 2.29B
Net income -154M -135M -125M -115M -217M -14.71B -221M -1.49B -583M -7.22B -577M -564M -24.94B -162M -142M -132M -121M -230M -15.54B -234M -1.57B -616M -7.63B -610M -596M -26.35B
Net Debt -512M -449M -416M -383M -724M -49B -738M -4.96B -1.94B -24.06B -1.92B -1.88B -83.11B -404M -354M -328M -302M -571M -38.68B -583M -3.91B -1.53B -19B -1.52B -1.48B -65.6B
Logo Bicycle Therapeutics plc
Bicycle Therapeutics plc is a United Kingdom-based clinical-stage biopharmaceutical company developing a class of medicines, referred to as Bicycle molecules, for diseases that are underserved by existing therapeutics. Bicycle molecules are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. The Company is evaluating zelenectide pevedotin, a Bicycle Toxin Conjugate (BTC) targeting Nectin-4, a well-validated tumor antigen; BT5528, a BTC targeting EphA2, a historically undruggable target, and BT7480, a Bicycle Tumor-Targeted Immune Cell Agonist (Bicycle TICA) targeting Nectin-4 and agonizing CD137, in Company-sponsored clinical trials. Additionally, the Company is developing Bicycle Radio Conjugates (BRC) for radiopharmaceutical use and, through various partnerships, is exploring the use of Bicycle technology to develop therapies for diseases beyond oncology.
Employees
288
Date Price Change Volume
14/07/26 USD 4.350 -1.36% 296,883
10/07/26 USD 4.410 +5.50% 804,201
09/07/26 USD 4.180 -2.34% 577,309
08/07/26 USD 4.280 -2.28% 337,115
07/07/26 USD 4.380 +0.69% 507,412
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
4.410USD
Average target price
12.62USD
Spread / Average Target
+186.28%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. BCYC Stock